Get the Stockscreener App
123.77
5.53%
6.49
Mirum Pharmaceuticals Inc stock is traded at $123.77, with a volume of 3.35M.
It is up +5.53% in the last 24 hours and up +25.15% over the past month.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
See More
Previous Close:
$117.28
Open:
$116.51
24h Volume:
3.35M
Relative Volume:
3.33
Market Cap:
$7.55B
Revenue:
$521.31M
Net Income/Loss:
$-23.36M
P/E Ratio:
-258.88
EPS:
-0.4781
Net Cash Flow:
$54.87M
1W Performance:
+15.53%
1M Performance:
+25.15%
6M Performance:
+56.16%
1Y Performance:
+144.80%
1-Day Range:
$113.41
$124.44
1-Week Range:
$105.18
$124.44
52-Week Range:
$47.89
$124.44
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
123.77 | 7.55B | 521.31M | -23.36M | 54.87M | -0.4781 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-25 | Initiated | TD Cowen | Buy |
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Enterprise value to revenue forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Price to sales forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Understanding Momentum Shifts in (MIRM) - Stock Traders Daily
Price to earnings forward of Mirum Pharmaceuticals, Inc. – HAM:08D - TradingView
MIRM, INCY report positive rare disease data as FDA begins NDA review - MSN
MIRM Forecast — Price Target — Prediction for 2027 - TradingView
Mirum Pharmaceuticals Stock Surges 18%, With A 8-Day Winning Spree - Trefis
Mirum Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIRM) - TradingView
08D Forecast — Price Target — Prediction for 2027 - TradingView
Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data? - Insider Monkey
Mirum Pharmaceuticals stock hits all-time high at 114.99 USD - Investing.com
Mirum Pharmaceuticals stock hits all-time high at 114.99 USD By Investing.com - Investing.com India
Values First Advisors, Inc.'s Mirum Pharmaceuticals Inc(MIRM) Holding History - GuruFocus
Mirum Shareholders Approve Directors, Auditors and Compensation - The Globe and Mail
Mirum Pharmaceuticals StockAnalyst views and sector check at week’s end - AD HOC NEWS
Insider Sell: Jolanda Howe Sells Shares of Mirum Pharmaceuticals Inc (MIRM) - GuruFocus
Mirum (MIRM) SVP Jolanda Howe sells 2,594 shares under Rule 10b5-1 plan - Stock Titan
Mirum Pharmaceuticals, Inc. (MIRM) reports Q1 loss, beats revenue estimates - MSN
Mirum Pharmaceuticals (MIRM) stockholders back 2026 directors, auditor and pay package - Stock Titan
Mirum Pharmaceuticals Inc (MIRM) Institutional Confidence - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mirum (MIRM) director Michael G. Grey awarded RSUs and $101 stock options - Stock Titan
Mirum Pharmaceuticals (MIRM) director granted new options and deferred stock units - Stock Titan
Director at Mirum (MIRM) awarded deferred stock units and options - Stock Titan
Mirum Pharmaceuticals Inc (MIRM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MIRM (NASDAQ) director plans sale of 2,594 shares via Morgan Stanley - Stock Titan
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - TradingView
Mirum Pharmaceuticals (MIRM) director granted options and 1,980 deferred stock units - Stock Titan
Avoiding Lag: Real-Time Signals in (MIRM) Movement - Stock Traders Daily
MIRM Maintained by Citizens -- Price Target Raised to $146 - GuruFocus
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - TradingView
H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Citizens raises Mirum Pharmaceuticals stock price target on drug deal By Investing.com - Investing.com Australia
Citizens raises Mirum Pharmaceuticals stock price target on drug deal - Investing.com
Mirum and Incyte's zilurgisertib shows positive phase 2 data in FOP - MSN
Mirum Pharmaceuticals, Inc. and Incyte Report Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - marketscreener.com
Here's what key metrics tell us about Mirum Pharmaceuticals (MIRM) Q1 earnings - MSN
MIRM Maintains Overweight Rating -- Price Target Raised to $150 - GuruFocus
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $150.00 Price Target at Morgan Stanley - MarketBeat
Why is Mirum Pharmaceuticals (MIRM) down 10.1% since last earnings report? - MSN
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 5,000 Shares of Stock - MarketBeat
Mirum Pharmaceuticals CFO Eric Bjerkholt sells $469k in shares - Investing.com UK
Mirum Pharmaceuticals CFO Eric Bjerkholt sells $469k in shares By Investing.com - Investing.com India
Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares after option exercise - Stock Titan
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):